| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
310,240,000 |
| Market
Cap: |
6.74(B) |
| Last
Volume: |
1,506,385 |
Avg
Vol: |
2,434,266 |
| 52
Week Range: |
$18.78 - $24.13 |
|
| Level
I Sector: |
Industrials |
| Level
II Sector: |
Diversified Services |
| Level
III Sector: |
Research Services |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : 17.5 |
| Insider 6 Months : 18.9 |
| Insider 3/6 Months : 36.8 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Exelixis is an oncology-focused biotechnology company that engages in the discovery, development and commercialization of new medicines for cancers. Co.'s products include: CABOMETYX® (cabozantinib) tablets approved for renal cell carcinoma, and for previously treated hepatocellular carcinoma; and COMETRIQ® (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The other products are: COTELLIC® (cobimetinib), an inhibitor of MEK approved as part of a combination regimen to treat forms of melanoma; and MINNEBRO® (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
425,000 |
615,000 |
735,409 |
735,409 |
| Total Buy Value |
$8,733,955 |
$12,666,689 |
$15,268,727 |
$15,268,727 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
2 |
3 |
4 |
4 |
| Total Shares Sold |
80,531 |
216,700 |
593,372 |
1,012,962 |
| Total Sell Value |
$1,755,807 |
$4,825,489 |
$12,725,795 |
$20,083,859 |
| Total People Sold |
5 |
7 |
9 |
12 |
| Total Sell Transactions |
5 |
9 |
16 |
27 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hessekiel Jeffrey |
EVP, General Counsel & Sec |
• – – |
2023-04-05 |
4 |
OE |
$14.74 |
$205,328 |
D/D |
13,930 |
621,365 |
|
- |
|
| Senner Christopher J. |
EVP and CFO |
• – – |
2023-04-03 |
4 |
A |
$0.00 |
$0 |
D/D |
85,414 |
590,077 |
|
- |
|
| Goodman Vicki L |
EVP, Prod Dev & Med Aff &CMO |
• – – |
2023-04-03 |
4 |
A |
$0.00 |
$0 |
D/D |
82,566 |
307,654 |
|
- |
|
| Hessekiel Jeffrey |
EVP, General Counsel & Sec |
• – – |
2023-04-03 |
4 |
A |
$0.00 |
$0 |
D/D |
79,719 |
607,435 |
|
- |
|
| Haley Patrick J. |
EVP, Commercial |
• – – |
2023-04-03 |
4 |
A |
$0.00 |
$0 |
D/D |
79,719 |
332,577 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2023-04-03 |
4 |
A |
$0.00 |
$0 |
D/D |
313,185 |
642,318 |
|
- |
|
| Aftab Dana |
CSO/EVP Disc & Trans Research |
• – – |
2023-04-03 |
4 |
A |
$0.00 |
$0 |
D/D |
68,331 |
419,803 |
|
- |
|
| Wyszomierski Jack L |
Director |
– • – |
2023-03-10 |
4 |
AS |
$16.61 |
$254,133 |
D/D |
(15,300) |
317,467 |
|
19% |
|
| Wyszomierski Jack L |
Director |
– • – |
2023-03-10 |
4 |
OE |
$6.30 |
$252,000 |
D/D |
40,000 |
332,767 |
|
- |
|
| Hessekiel Jeffrey |
EVP, General Counsel & Sec |
• – – |
2023-03-01 |
4 |
AS |
$17.13 |
$1,333,742 |
D/D |
(77,860) |
527,716 |
|
10% |
|
| Hessekiel Jeffrey |
EVP, General Counsel & Sec |
• – – |
2023-03-01 |
4 |
OE |
$14.74 |
$410,656 |
D/D |
27,860 |
605,576 |
|
- |
|
| Aftab Dana |
CSO/EVP Disc & Trans Research |
• – – |
2023-02-28 |
4 |
S |
$17.50 |
$1,443,575 |
D/D |
(82,490) |
351,472 |
|
-12% |
|
| Aftab Dana |
CSO/EVP Disc & Trans Research |
• – – |
2023-02-28 |
4 |
OE |
$14.74 |
$1,215,903 |
D/D |
82,490 |
433,962 |
|
- |
|
| Aftab Dana |
CSO/EVP Disc & Trans Research |
• – – |
2023-02-27 |
4 |
S |
$17.50 |
$175 |
D/D |
(10) |
351,472 |
|
-11% |
|
| Aftab Dana |
CSO/EVP Disc & Trans Research |
• – – |
2023-02-27 |
4 |
OE |
$14.74 |
$147 |
D/D |
10 |
351,482 |
|
- |
|
| Garber Alan M |
Director |
– • – |
2023-02-21 |
4 |
AS |
$17.49 |
$699,600 |
D/D |
(40,000) |
31,417 |
|
10% |
|
| Garber Alan M |
Director |
– • – |
2023-02-21 |
4 |
OE |
$6.30 |
$252,000 |
D/D |
40,000 |
71,417 |
|
- |
|
| Senner Christopher J. |
EVP and CFO |
• – – |
2023-02-15 |
4 |
D |
$18.08 |
$95,426 |
D/D |
(5,278) |
504,663 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2023-02-15 |
4 |
D |
$18.08 |
$208,318 |
D/D |
(11,522) |
329,133 |
|
- |
|
| Aftab Dana |
CSO/EVP Disc & Trans Research |
• – – |
2023-02-15 |
4 |
D |
$18.08 |
$27,644 |
D/D |
(1,529) |
351,472 |
|
- |
|
| Hessekiel Jeffrey |
EVP, General Counsel & Sec |
• – – |
2023-02-15 |
4 |
D |
$18.08 |
$34,876 |
D/D |
(1,929) |
577,716 |
|
- |
|
| Goodman Vicki L |
EVP, Prod Dev & Med Aff &CMO |
• – – |
2023-02-15 |
4 |
D |
$18.08 |
$312,766 |
D/D |
(17,299) |
225,088 |
|
- |
|
| Haley Patrick J. |
EVP, Commercial |
• – – |
2023-02-15 |
4 |
D |
$18.08 |
$28,132 |
D/D |
(1,556) |
252,858 |
|
- |
|
| Feldbaum Carl B |
Director |
– • – |
2023-02-09 |
4 |
S |
$17.78 |
$711,200 |
D/D |
(40,000) |
18,701 |
|
-8% |
|
| Feldbaum Carl B |
Director |
– • – |
2023-02-09 |
4 |
OE |
$6.30 |
$252,000 |
D/D |
40,000 |
58,701 |
|
- |
|
1437 Records found
|
|
Page 5 of 58 |
|
|
0.19 (0.87%) 
